Fisher Asset Management LLC Acquires Shares of 65,114 Protagonist Therapeutics, Inc. $PTGX

Fisher Asset Management LLC acquired a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 65,114 shares of the company’s stock, valued at approximately $5,687,000.

Several other large investors have also bought and sold shares of the company. Smartleaf Asset Management LLC boosted its position in Protagonist Therapeutics by 11.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock valued at $91,000 after acquiring an additional 146 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after acquiring an additional 156 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its position in Protagonist Therapeutics by 1.5% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 13,393 shares of the company’s stock valued at $1,170,000 after acquiring an additional 193 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Protagonist Therapeutics by 8.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,959 shares of the company’s stock valued at $258,000 after acquiring an additional 221 shares in the last quarter. Finally, Parkman Healthcare Partners LLC boosted its position in Protagonist Therapeutics by 0.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 61,849 shares of the company’s stock valued at $4,109,000 after acquiring an additional 253 shares in the last quarter. 98.63% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on PTGX shares. TD Cowen lifted their price objective on Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Johnson Rice reissued a “buy” rating on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. Weiss Ratings reissued a “sell (d+)” rating on shares of Protagonist Therapeutics in a research report on Friday, May 15th. JPMorgan Chase & Co. boosted their price target on Protagonist Therapeutics from $95.00 to $106.00 and gave the stock an “overweight” rating in a research report on Thursday, March 19th. Finally, Citigroup reissued an “outperform” rating on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $115.21.

Protagonist Therapeutics Stock Down 1.8%

Shares of PTGX opened at $100.41 on Friday. The business’s 50 day moving average price is $101.68 and its 200-day moving average price is $92.00. Protagonist Therapeutics, Inc. has a 52 week low of $45.43 and a 52 week high of $107.84. The stock has a market cap of $6.46 billion, a P/E ratio of -55.48 and a beta of 1.89.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The firm had revenue of $56.37 million for the quarter, compared to analysts’ expectations of $11.70 million. On average, equities analysts anticipate that Protagonist Therapeutics, Inc. will post 3.29 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total value of $7,509,000.00. Following the transaction, the chief executive officer directly owned 523,478 shares of the company’s stock, valued at approximately $52,410,617.36. This represents a 12.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Bryan Giraudo sold 36,000 shares of Protagonist Therapeutics stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $100.14, for a total value of $3,605,040.00. Following the completion of the sale, the director directly owned 27,825 shares of the company’s stock, valued at approximately $2,786,395.50. The trade was a 56.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 254,345 shares of company stock worth $25,810,506 in the last three months. Corporate insiders own 5.19% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.